Literature DB >> 24287197

Extraglandular manifestations of primary Sjögren's syndrome.

Sabatino Ienopoli1, Steven E Carsons.   

Abstract

Sjögren syndrome is a chronic autoimmune disease that typically affects the salivary and lacrimal glands. Aside from the common glandular signs and symptoms, Sjögren syndrome may also cause mononuclear infiltration and immune complex deposition involving extraglandular sites producing several extraglandular manifestations (EGM). The prevalence of EGMs varies greatly depending on the particular manifestation. This article examines the ways that EGMs may present in patients with primary Sjögren syndrome. The focus is on the more prevalent and significant EGMs including involvement of the nervous system, pulmonary manifestations, vasculitis associated with primary Sjögren syndrome, and arthropathy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arthropathy; Extraglandular; Sjögren's syndrome; Vasculitis

Mesh:

Year:  2014        PMID: 24287197     DOI: 10.1016/j.coms.2013.09.008

Source DB:  PubMed          Journal:  Oral Maxillofac Surg Clin North Am        ISSN: 1042-3699            Impact factor:   2.802


  11 in total

1.  Gastrointestinal and liver lesions in primary childhood Sjögren syndrome.

Authors:  Yasuyo Kashiwagi; Tatsuro Hatsushika; Norito Tsutsumi; Soken Go; Shigeo Nishimata; Hisashi Kawashima
Journal:  Clin Rheumatol       Date:  2017-03-20       Impact factor: 2.980

Review 2.  Connective Tissue Disorder-Associated Vasculitis.

Authors:  Aman Sharma; Aadhaar Dhooria; Ashish Aggarwal; Manish Rathi; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

3.  Patient burden of Sjögren's: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity.

Authors:  Katherine M Hammitt; April N Naegeli; Remon W M van den Broek; Julie A Birt
Journal:  RMD Open       Date:  2017-09-17

Review 4.  Nephrological disorders and neurological involvement in pediatric primary Sjogren syndrome:a case report and review of literature.

Authors:  Jingya Zhao; Qin Chen; Yunyun Zhu; Meng Zhao; Jun Liu; Zhenzhong Zhang; Xiaoting Gong
Journal:  Pediatr Rheumatol Online J       Date:  2020-05-24       Impact factor: 3.054

5.  miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome.

Authors:  Joan Ní Gabhann-Dromgoole; Conor C Murphy; Qistina Pilson; Siobhan Smith; Caroline A Jefferies
Journal:  Sci Rep       Date:  2020-05-04       Impact factor: 4.379

6.  An Innovative Online Qualitative Study to Explore the Symptom Experience of Patients with Primary Sjögren's Syndrome.

Authors:  Kerry Gairy; Keith Ruark; Susan M Sinclair; Helen Brandwood; Linda Nelsen
Journal:  Rheumatol Ther       Date:  2020-07-28

Review 7.  Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.

Authors:  Amrita Srivastava; Helen P Makarenkova
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

8.  Orofacial Manifestations and Temporomandibular Disorders of Sjögren Syndrome: An Observational Study.

Authors:  Vito Crincoli; Mariasevera Di Comite; Mariateresa Guerrieri; Rossana Patricia Rotolo; Luisa Limongelli; Angela Tempesta; Florenzo Iannone; Angela Rinaldi; Giovanni Lapadula; Gianfranco Favia
Journal:  Int J Med Sci       Date:  2018-03-08       Impact factor: 3.738

9.  Clinical Profile and Significance of Mucocutaneous Lesions of Primary Sjögren's Syndrome: A Large Cross-sectional Study with 874 Patients.

Authors:  Lei Xuan; Yi-Dong Zhang; Li Li; Yue-Ping Zeng; Hao-Ze Zhang; Jing Wang; Zhen-Hua Dong
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

Review 10.  Ophthalmologic Manifestations of Primary Sjögren's Syndrome.

Authors:  Anna Maria Roszkowska; Giovanni William Oliverio; Emanuela Aragona; Leandro Inferrera; Alice Antonella Severo; Federica Alessandrello; Rosaria Spinella; Elisa Imelde Postorino; Pasquale Aragona
Journal:  Genes (Basel)       Date:  2021-03-04       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.